Description

Delmitide acetate, also known as RDP58 acetate, is a rationally designed, orally active decapeptide composed entirely of d-amino acids. It demonstrates potent immunomodulatory and anti-inflammatory activity through the inhibition of key pro-inflammatory cytokines such as TNF-?, IFN-?, and IL-12, while enhancing the expression of the antioxidant enzyme heme oxygenase-1 .

Preclinical and early clinical evaluations have shown that Delmitide acetate can significantly reduce inflammation in ulcerative colitis models, with a favorable safety and tolerability profile.

Manufactured under GMP-compliant conditions, this peptide is supplied as a lyophilized powder with a purity of 98.55% (HPLC-grade), ensuring reproducible results across research and screening workflows.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Delmitide acetate functions as a potent inhibitor of inflammatory signaling by disrupting the MyD88–IRAK–TRAF6 complex, leading to reduced transcription and production of TNF-?, IFN-?, IL-12, and other cytokines. It also induces the expression of the cytoprotective enzyme heme oxygenase-1.

Research Applications

• Ulcerative Colitis Studies: Demonstrates significant clinical success and histological improvement at 200–300 mg doses in randomized trials of ulcerative colitis.

• Inflammatory Skin Models: Effectively reduces inflammation in dermatitis models when applied topically.

• Cytokine Pathway Analysis: Ideal for dissecting NF-?B, MAPK, and MyD88-dependent signaling in immune and epithelial cell systems.

• Oxidative Stress & Antioxidant Response: Valuable for investigations into redox biology due to its up-regulation of heme oxygenase-1.

Development & Formulation Notes

Stock Solutions & Handling

Dissolve in sterile water or buffer to achieve concentrations between 1–10 mM. Gentle heating (37 °C) or ultrasonic treatment may assist solubilization. Filter solutions through a 0.22 µm filter to ensure sterility. Use low-binding labware and consider adding carrier proteins for assays at low concentrations.

Assay Design

Employ dose–response studies to establish IC?? for cytokine suppression. Include time-course sampling for cytokine profiling (e.g., TNF-?, IL-12). Use both in vitro immune cell assays and in vivo inflammatory models for broader validation.

Combinations & Pathway Mapping

Test synergistically with anti-TNF or COX inhibitors to explore additive or complementary effects. Include molecular readouts (e.g., qPCR, ELISA, western blot) to characterize pathway modulation.

Disclaimer

Delmitide acetate is provided strictly for research use only. It is not a drug, diagnostic, or therapeutic agent and is not licensed for human or veterinary use. Handle with appropriate PPE and dispose of waste per institutional regulations. All data presented are based on preclinical and early clinical research. Users are responsible for verifying applicability and regulatory compliance in their experimental context.

Keywords

Delmitide acetate; RDP58 acetate; D-decapeptide anti-inflammatory; TNF-? IFN-? IL-12 inhibitor; ulcerative colitis research peptide; heme oxygenase-1 inducer; GMP peptide; CAS 501019-16-5; research-use-only peptide.

Packaging & Availability

• Standard Packs: 1 mg, 5 mg, 10 mg (custom sizes upon request)

• Bulk/Wholesale: Multi-gram lots with batch continuity and scheduling available

• Documentation: CoA, HPLC trace, MS identity included; enhanced QC data available for audits

Quality Assurance

Manufactured under strict GMP protocols. Batch testing ensures identity (MS), purity (HPLC), residual solvents, moisture, and appearance. Endotoxin and bioburden assessments can be provided upon request.

Custom Services

• Custom aliquoting and labeling aligned with LIMS or ELN systems

• Buffer and excipient formulation support for oral or topical delivery studies

• Stability study planning for long-term storage or shipping scenarios

• Experimental planning support for inflammatory disease models